Company intelligence / Profile preview

Hangzhou Aida Pharmaceuticals

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Hangzhou Aida Pharmaceuticals is a Chinese biopharmaceutical company specializing in the research, development, and commercialization of innovative anti-tumor medications. Founded in 2002 and headquartered in Hangzhou, the company focuses on small molecule targeted therapies and DNA-interacting agents. Its lead candidate, Amonafide L-malate, has been investigated in late-stage clinical trials for indications such as acute myeloid leukemia and various solid tumors. The company aims to address unmet medical needs in oncology through its dedicated R&D center and manufacturing capabilities located in the Hangzhou Hi-Tech Zone.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

etimicin

Unknown

Beyond the preview

Go deeper on Hangzhou Aida Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Aida Pharmaceuticals.

Explore the full profile